Is MiMedx Group, Inc. (MDXG) a Buy, Sell, or Hold?
NASDAQ : MDXG
MiMedx Group, Inc.
$4.2 USD
$0.07 (1.69%)
- Volume
- 531.89K
- Average Volume
- 1.46M
- Market Capitalization
- $625.57M
- P/E Ratio
- 20.48
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $7.99
- Year Low
- $3.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.39
Company Overview
NASDAQ
Joseph H. Capper
Biotechnology
Healthcare
MDXG
808
US
USD
Liquidity Metrics
0.07
5.39
4.81
3.59
0.00
Sales & Valuation
$418.63M
1.61
2.57
9.55
0.44
Profitability
$0.32
$48.58M
7.88%
10.87%
12.86%
9.94%
P/E Metrics
20.48
-0.82
-0.82
Analyst Price Target & Rating
$10.00
$10.00
$10.00
4/5
15 Analysts
-58.00%
Financial Health Scores
7.86
6/9
$195.78M
$308.68M
$65.74M
$43.98M
Key Metrics (TTM)
$483.39M
1.24
8.44
5.39
12.86%
10.81%
4.92%
10.47%
$2.76
116 days
Company Executives
| Name | Title |
|---|---|
| Kimberly Maersk-Moller | Chief Commercial Officer |
| Tracy Chastain | Chief Human Resources Officer |
| Matthew Notarianni | Head of Investor Relations |
| William F. Hulse | General Counsel & Chief Administrative Officer |
| Eric A. Smith | Senior VP of Marketing & International |
| Joseph H. Capper | Chief Executive Officer & Director |
| Douglas C. Rice | Chief Financial Officer |
| David H. Mason Jr. | Chief Medical Officer |
| John Harper | SVP of R&D & Medical Affairs and Chief Scientific Officer |
| Mark Graves | Senior Vice President & Chief Compliance Officer |
| Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications |
Poll Results
No votes yet today — be the first to share your view!
About MiMedx Group, Inc. (NASDAQ:MDXG) Stock
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, se ... mi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
2026-07-20 08:00:00
MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026.
2026-05-21 15:45:00
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
2026-05-21 08:45:00
MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.
2026-05-19 18:15:00
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-05-15 00:00:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG PR Newswire
2026-05-14 23:01:00
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
2026-05-12 16:52:00
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is the Options Market Predicting a Spike in MiMedx Group Stock?
2026-05-11 15:40:29
Investors need to pay close attention to MDXG stock based on the movements in the options market lately.
Frequently Asked Questions
-
What is the current MiMedx Group, Inc. (MDXG) stock price?
-
MiMedx Group, Inc.(NASDAQ:MDXG) stock price is $4.2 in the last trading session. During the trading session, MDXG stock reached the peak price of $7.99 while $3.03 was the lowest point it dropped to. The percentage change in MDXG stock occurred in the recent session was 1.69% while the dollar amount for the price change in MDXG stock was $0.07.
-
MDXG's industry and sector of operation?
-
The NASDAQ listed MDXG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MDXG?
-
Kimberly Maersk-Moller | Chief Commercial Officer
Tracy Chastain | Chief Human Resources Officer
Matthew Notarianni | Head of Investor Relations
William F. Hulse | General Counsel & Chief Administrative Officer
Eric A. Smith | Senior VP of Marketing & International -
How many employees does MDXG have?
-
Number of MDXG employees currently stands at 808. MDXG operates from 1775 West Oak Commons Court, NE, Marietta, GA 30062, US.
-
Link for MDXG official website?
-
Official Website of MDXG is: https://www.mimedx.com
-
How do I contact MDXG?
-
MDXG could be contacted at phone #770 651 9100 and can also be accessed through its website. MDXG operates from 1775 West Oak Commons Court, NE, Marietta, GA 30062, US.
-
How many shares of MDXG are traded daily?
-
The average number of MDXG shares traded daily for last 3 months was 1.46M.
-
What is the market cap of MDXG currently?
-
The market value of MDXG currently stands at $625.57M with its latest stock price at $4.2